May. 7 at 9:31 AM
$XBIO
The market is still treating this like a tiny speculative biotech, but the story is getting harder to ignore.
NETs, cfDNA, DNase, CAR-T enhancement, solid tumor resistance, pancreatic cancer, Scripps collaboration.
This is not random buzzword biotech. This is a focused tumor microenvironment platform sitting in front of multiple major oncology problems.
If human data starts validating even part of the mechanism, the current valuation will look ridiculous.
